MedTrace Logo

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

NCT01560260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-09-21

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Carney Complex
  • Chondrosarcoma
  • Gastrointestinal Stromal Tumor
  • Paraganglioma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Linsitinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Margaret von Mehren · Sarcoma Alliance for Research through Collaboration

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01560260 on ClinicalTrials.gov